Ropes & Gray represented Cullinan Oncology in the deal. Cullinan Oncology announced a strategic collaboration with Taiho Pharmaceutical under which Taiho will acquire Cullinan Oncology’s subsidiary Cullinan...
Cullinan Oncology’s Collaboration with Taiho Pharmaceutical
EQRx’s Collaboration with Insilico Medicine
Ropes & Gray advised EQRx in the deal while Wilson Sonsini Goodrich & Rosati represented InSilico. EQRx annlounced a strategic collaboration with Insilico Medicine to jointly...
ImmunoGen’s Global Multi-Target License Agreement with Eli Lilly
Ropes & Gray advised ImmunoGen on the deal. ImmunoGen, a leader in the field of antibody-drug conjugates for the treatment of cancer, announced a global, multi-year...
Ovid Therapeutics’ Partnership With Healx
Ropes & Gray advised Ovid Therapeutics on the deal. Ovid Therapeutics announced a strategic partnership with U.K.-based Healx, an AI-powered technology company, that granted Healx the...
EQRx and Evotec’s Integrated Drug Discovery and Development Partnership
Ropes & Gray advised EQRx in the deal. EQRx announced a partnership to leverage Germany-based Evotec’s data-driven integrated drug discovery and development platform across different drug...
EQRx’s Collaboration with Abdul Latif Jameel Health
Ropes & Gray advised EQRx in the deal. EQRx announced a strategic collaboration with Abdul Latif Jameel Health, part of the international diversified family business of...
Verastem Oncology’s Collaboration With Mirati Therapeutics
Ropes & Gray advised Verastem Oncology in the deal. Verastem Oncology announced a collaboration to evaluate Mirati Therapeutics’ investigational KRAS inhibitor drug with Verastem’s investigational inhibitor drug...
Ironwood Pharmaceuticals’ Rare Autoimmune Disease Collaboration with COUR Pharmaceuticals
Ropes & Gray represented Ironwood Pharmaceuticals in the collaboration and license option agreement with COUR Pharmaceutical Development Company. The agreement gives Ironwood an option to acquire...
EQRx’s Partnership with Absci
Ropes & Gray advised EQRx on the deal. EQRx announced a strategic drug discovery and development partnership to use Absci’s artificial intelligence and synthetic biology platform...
EQRx’ Drug Collaboration with Exscientia
Ropes & Gray advised EQRx on the deal. EQRx closed a strategic drug creation, development, and commercialization collaboration with Exscientia. The collaboration combines Exscientia’s leading AI-driven drug...
Blackstone Life Sciences’ $250 Million Investment in Cellex Group
Noerr and Morgan, Lewis & Bockius advised Cellex Cell Professionals GmbH on the deal. Ropes & Gray advised Blackstone Life Sciences. The Dresden-based Cellex Group announced...